Lipella Pharmaceuticals (LIPO) Proxy Filing summary

Executive summary

• Special Meeting scheduled for December 6, 2024, to vote on issuing 20% or more of outstanding common stock via a new equity line of credit (ELOC).

• The ELOC is intended to help regain compliance with Nasdaq’s minimum stockholders’ equity requirement and support business strategy and working capital.

• Board unanimously recommends voting in favor of the proposal to enable flexible access to capital.

• If approved, the company can issue shares exceeding 19.99% of current outstanding stock, potentially diluting existing shareholders.

• If not approved, risk of Nasdaq delisting increases, limiting capital access and growth potential.

Voting matters and shareholder proposals

• Main proposal: Approve issuance of 20% or more of outstanding common stock under a securities purchase agreement for an ELOC.

• Only shareholders of record as of October 28, 2024, are eligible to vote.

• Voting can be done online, by phone, or by mail; proxies are revocable.

• Abstentions and broker non-votes do not affect the outcome but count toward quorum.

• No dissenter’s rights are available for this proposal.

Board of directors and corporate governance

• Dr. Jonathan Kaufman serves as President, CEO, and Chairman; he is named as proxy for voting.

• Board is responsible for soliciting proxies and making recommendations.

• Board will vote proxies as specified or, if unspecified, as recommended.